NATCO Pharma Limited (BOM:524816)

NATCO Pharma Statistics

Total Valuation

NATCO Pharma has a market cap or net worth of INR 181.96 billion. The enterprise value is 167.81 billion.

Market Cap	181.96B
Enterprise Value	167.81B

Important Dates

The last earnings date was Friday, May 29, 2026.

Earnings Date	May 29, 2026
Ex-Dividend Date	Feb 18, 2026

Share Statistics

Current Share Class	179.11M
Shares Outstanding	n/a
Shares Change (YoY)	-0.00%
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	29.49%
Owned by Institutions (%)	10.83%
Float	83.54M

Valuation Ratios

The trailing PE ratio is 12.83 and the forward PE ratio is 24.38.

PE Ratio	12.83
Forward PE	24.38
PS Ratio	4.16
PB Ratio	1.97
P/TBV Ratio	2.03
P/FCF Ratio	13.19
P/OCF Ratio	10.29
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.42, with an EV/FCF ratio of 12.16.

EV / Earnings	11.83
EV / Sales	3.83
EV / EBITDA	9.42
EV / EBIT	10.66
EV / FCF	12.16

Financial Position

The company has a current ratio of 3.01, with a Debt / Equity ratio of 0.08.

Current Ratio	3.01
Quick Ratio	1.79
Debt / Equity	0.08
Debt / EBITDA	0.41
Debt / FCF	0.52
Interest Coverage	41.62

Financial Efficiency

Return on equity (ROE) is 16.85% and return on invested capital (ROIC) is 20.85%.

Return on Equity (ROE)	16.85%
Return on Assets (ROA)	9.69%
Return on Invested Capital (ROIC)	20.85%
Return on Capital Employed (ROCE)	16.26%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	10.42M
Profits Per Employee	3.38M
Employee Count	4,199
Asset Turnover	0.44
Inventory Turnover	0.11

Taxes

In the past 12 months, NATCO Pharma has paid 1.19 billion in taxes.

Income Tax	1.19B
Effective Tax Rate	7.73%

Stock Price Statistics

The stock price has increased by +17.89% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+17.89%
50-Day Moving Average	1,083.04
200-Day Moving Average	925.02
Relative Strength Index (RSI)	33.50
Average Volume (20 Days)	60,420

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NATCO Pharma had revenue of INR 43.76 billion and earned 14.19 billion in profits. Earnings per share was 79.20.

Revenue	43.76B
Gross Profit	42.79B
Operating Income	15.28B
Pretax Income	15.37B
Net Income	14.19B
EBITDA	17.34B
EBIT	15.28B
Earnings Per Share (EPS)	79.20

Balance Sheet

The company has 21.29 billion in cash and 7.14 billion in debt, with a net cash position of 14.15 billion.

Cash & Cash Equivalents	21.29B
Total Debt	7.14B
Net Cash	14.15B
Net Cash Per Share	n/a
Equity (Book Value)	92.21B
Book Value Per Share	514.92
Working Capital	33.71B

Cash Flow

In the last 12 months, operating cash flow was 17.68 billion and capital expenditures -3.88 billion, giving a free cash flow of 13.80 billion.

Operating Cash Flow	17.68B
Capital Expenditures	-3.88B
Depreciation & Amortization	2.07B
Net Borrowing	4.24B
Free Cash Flow	13.80B
FCF Per Share	n/a

Margins

Gross margin is 97.78%, with operating and profit margins of 34.91% and 32.42%.

Gross Margin	97.78%
Operating Margin	34.91%
Pretax Margin	35.13%
Profit Margin	32.42%
EBITDA Margin	39.63%
EBIT Margin	34.91%
FCF Margin	31.54%

Dividends & Yields

This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 0.49%.

Dividend Per Share	5.00
Dividend Yield	0.49%
Dividend Growth (YoY)	-16.67%
Years of Dividend Growth	n/a
Payout Ratio	6.31%
Buyback Yield	0.00%
Shareholder Yield	0.50%
Earnings Yield	7.80%
FCF Yield	7.58%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on November 26, 2015. It was a forward split with a ratio of 5.

Last Split Date	Nov 26, 2015
Split Type	Forward
Split Ratio	5

Scores

Altman Z-Score	n/a
Piotroski F-Score	5